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Gonadal function was assessed in male lymphoma survivors based on serum hormone levels (LH, FSH, testosterone, SHBG), and was
related to treatment, age and observation time. Male patients p50 years at diagnosis treated for Hodgkin’s (HL) and/or non-
Hodgkin’s lymphoma (NHL) at the Norwegian Radium Hospital from 1 January 1980 to 31 December 2002 were included. Five
treatment groups were defined: 1: radiotherapy only and/or low gonadotoxic chemotherapy (both HL and NHL)(‘No/low’), 2:
medium gonadotoxicity chemotherapy for NHL (‘med-NHL’), 3: medium gonadotoxicity chemotherapy for HL (‘med-HL’), 4: highly
gonadotoxic chemotherapy for NHL (‘high-NHL’), 5: highly gonadotoxic chemotherapy for HL (‘high-HL’). Gonadal hormone levels
were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG
and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine
hypogonadism). One hundred and forty-four (49%) of the patients had normal gonadal hormones, 60 (20%) displayed exocrine
hypogonadism and almost one-third (n¼90, 30%) had endocrine hypogonadism. Compared to those treated with no/low
gonadotoxic chemotherapy patients from all other treatment groups had significantly elevated risk for exocrine hypogonadism.
Patients from the other treatment groups, except those in the med-NHL group, also had significantly elevated risk for endocrine
hypogonadism compared with the group treated with no/low gonadotoxic chemotherapy. Men aged above 50 years at survey were
about five times more likely to have endocrine hypogonadism compared with those less than 40 years. Because of the adverse health
effects following long-lasting endocrine hypogonadism, gonadal hormones should be assessed regularly in male lymphoma survivors,
especially after treatment with alkylating agents and high-dose chemotherapy with autologous stem cell support and in male patients
who are 50 years and older.
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Testicular dysfunction can be a late side effect after cancer
treatment. It is known that post-treatment spermatogenesis in
male survivors after malignant lymphoma is dependent on the type
of chemotherapy, the drugs’ cumulative dose, the radiation doses
to the testicles from scattered or direct irradiation and the time
since last treatment (Lee et al, 2006).
Further, some studies have shown that pre-treatment sperma-
togenesis in survivors after Hodgkin’s lymphoma (HLSs) is
impaired at a greater degree than in survivors after non-Hodgkin’s
lymphoma (NHLSs) (Botchan et al, 1997; Fitoussi et al, 2000;
Rueffer et al, 2001). Post-treatment gonadal dysfunction may thus
be associated with pre-treatment fertility problems.
During recent years evidence has emerged that malignant
lymphoma survivors may have subnormal serum levels of
testosterone and/or elevated LH (Whitehead et al, 1982;
Viviani et al, 1991; Howell et al, 1999) However, there are a
few large studies confirming these findings, and even fewer studies
are published which compare HLSs with NHLSs. On the other
hand, endocrine hypogonadism may increase the risk of severe
health problems such as premature osteoporosis and insulin-
resistance (Finkelstein et al, 1987; Howell et al, 2000; Greenfield
et al, 2007).
In adult men the testicles have both endocrine (hormone
production) and exocrine (spermatogenesis) function, controlled
by the hypothalamus – pituitary – gonad axis. Gonadotropin-
releasing hormone (GnRH) from the hypothalamus promotes the
production of the luteinizing hormone (LH) and follicle-stimulat-
ing hormone (FSH) from the anterior pituitary. Simplified, LH
stimulates the Leydig cells to produce testosterone; FSH and
testosterone stimulate the Sertoli cells, which together provide
support for spermatogenesis.
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secondary hypogonadism. Primary hypogonadism is due to
testicular damage resulting in impaired spermatogenesis and/or
dysfunction of the Leydig cells. As a rule of thumb, elevated FSH
indicates impaired spermatogenesis, whereas permanently elevated
LH indicates Leydig cell dysfunction. Secondary hypogonadism is
caused by damage to the pituitary gland or hypothalamus, that is,
after cranial radiotherapy, and leads to decreased LH and FSH
followed by both exocrine and endocrine gonadal failure. Male
gonadal function can thus be screened by assessment of serum
levels of LH, FSH, testosterone, SHBG and sperm cell count and by
the consideration of fatherhood. In case of Leydig cell damage the
serum levels of testosterone are low and those of LH are often
elevated, though Greenfield et al (2007) recently has cast some
doubt about this correlation.
With this background, the aim of the present cross-sectional
study was to assess post-treatment gonadal function in a large
series of lymphoma patients in relation to treatment, age and
observation time emphasizing the possible differences between
HLSs and NHLSs.
PATIENTS AND METHODS
Patients
Eligible patients for the present postal cross-sectional study
fulfilled all the following criteria: 1: male patients p50 years at
diagnosis, 2: treated for Hodgkin’s lymphoma (HL) and/or non-
Hodgkin’s lymphoma (NHL), 3: registered in the lymphoma
database at the Norwegian Radium Hospital (NRH), 4: Period of
diagnosis from 1 January 1980 to 31 December 2002, 5: age above
18 years at the time of the survey (January 2007), 6: valid postal
address and 7: alive in June 2007.
Patients who had received total brain irradiation or scrotal
irradiation were excluded. Patients registered with both HL and
NHL was grouped according to their first diagnosis. Totally there
were 16 patients, of whom seven had their gonadal hormones
assessed. Of these seven, four were initially diagnosed with HL and
three with NHL, and later on they were diagnosed with a secondary
lymphoma.
Treatment
Treatment strategies of HL and NHL at the NRH for the period
1980–2002 have been described earlier (Hagemeister et al, 1987;
Merk et al, 1991; Evensen et al, 1994; Abrahamsen et al, 1996;
Holte et al, 1996; Hollender et al, 2000; Aurlien et al, 2001;
Seidemann et al, 2001; Sweetenham et al, 2001; Blystad et al, 2001a,
2001b; Smeland et al, 2004; Kiserud et al, 2007).
For the purpose of this study the total treatment of each patient,
thus both primary and eventual salvage therapy, was summarised
as recorded in the lymphoma database. As there is little knowledge
concerning damage of the Leydig cell function by chemotherapy,
we have categorised chemotherapy according to the expected
exocrine gonadal damage. Categories were created based mainly
on literature on post-treatment exocrine hypogonadism, as
reported in a previous study on post-treatment parenthood in
HLSs: low, medium and high chemotherapy-induced gonadotoxi-
city (Viviani et al, 1985; Howell and Shalet, 2001; Lee et al, 2006;
Kiserud et al, 2007). In addition, a group was constructed
including patients who had received radiotherapy only.
Analyses showed no differences with respect to gonadal
hormones between patients who had received supradiaphragmatic
RT only and those who had been irradiated with inverted Y/
inguinal or other infradiaphragmatic fields. In addition, there was
no difference between the group treated with radiotherapy only
and the group treated with low gonadotoxic chemotherapy.
The treatment groups were defined as follows: 1: radiotherapy
only and/or low gonadotoxic chemotherapy (both HL and NHL)
(‘No/low’), 2: medium gonadotoxicity chemotherapy for NHL
(‘med-NHL’), 3: medium gonadotoxicity chemotherapy for HL
(‘med-HL’), 4: highly gonadotoxic chemotherapy for NHL (‘high-
NHL’), 5: highly gonadotoxic chemotherapy for HL (‘high-HL’).
The different chemotherapy regimens were allocated to groups
1–5 as described in Table 1A, with chemotherapy regimens,
number of courses and type of radiotherapy for each treatment
group outlined in Tables 1B and 1C.
Study design
The cross-sectional study included serum hormone analyses and a
questionnaire assessing various aspects of quality of life. The
present analyses are restricted to gonadal hormones, whereas
quality of life aspects will be discussed in detail in a separate paper.
Blood samples for analyses of gonadal hormones (testosterone,
SHBG, LH, FSH) were to be drawn before noon by the patient’s GP
and mailed to the Hospital’s Department of Medical Biochemistry.
Patients with gonadal hormones indicating hypogonadism were
invited to an outpatient clinical examination and a control morning
blood sample. All analyses were performed at the same laboratory at
Rikshospitalet with E170 module for Modular Analytics, Roche
Professional Diagnostic, Germany. Normal ranges were: Testoster-
one: 9.0–31.0nmoll
 1,S H B G :1 5 – 8 5 n m o l l
 1,F S H o12.0Ul
 1,
LHo10.0Ul
 1. The testosterone/SHBG ratio was calculated for each
patient, as a surrogate for free testosterone, with testosterone/SHBG
ratio o0.25 indicating hypogonadism.
Table 1A Groups of chemotherapy according to expected gonado-
toxicity
Treatment groups Treatment
1. No chemotherapy/
Low gonadotoxic
chemotherapy
(both HL and NHL)
Radiotherapy only
ABVD/EBVP and similar
No/low
2. Medium gonadotoxic
chemotherapy NHL
CHOP/COP/CHOEP
p8 courses alone
CHOP p8 courses combined with high dose Mtx
Med-NHL MACOP B
BFM 90/93
Chlorambucil p.o.
MIME
3. Medium gonadotoxic
chemotherapy HL
LVPP p4 courses alone or combined with ABOD/
EBVP/dexa BEAM ( 2 courses)
OEPA+0–4 COPP
MIME
Med-HL
4. Highly gonadotoxic
chemotherapy NHL
CHOP 4 8 courses
CHOP¼8 courses combined with MIME, ENAP or
Chlorambucil
Maxi-CHOP X6 courses
High-NHL HDT with BEAM as conditioning regimen
HDT with cyclophosphamide and TBI as conditioning
regimen
5. Highly gonadotoxic
chemotherapy HL
LVPP 4 4 courses
LVPP¼4 courses combined with CHOP, MIME or
BEACOPP (4 courses)
BEACOPP 8 courses
High-HL HDT with BEAM as conditioning regimen
HDT with cyclophosphamide and TBI as conditioning
regimen
HDT¼high-dose chemotherapy with autologous stem cell support; TBI¼total body
irradiation.
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1.No chemo/low 2. Med-NHL 3. Med-HL 4. High-NHL 5. High-HL
N¼99 N¼73 N¼43 N¼43 N¼36
No. of
patients (%)
No. of
patients (%)
No. of
patients (%)
No. of
patients (%)
No. of
patients (%)
Chemotherapy only 10 (10) 30 (41) 6 (14) 7 (16) 10 (28)
Radiotherapy only 42 (42)
Chemotherapy+radiotherapy 47 (48) 43 (59) 37 (86) 36 (84) 26 (72)
1st relapse 6 8 11 24 13
X2nd relapse 1 1 2 10 3
ABVD/EBVP p8 courses
Doxorubicin p400mgm
 2
57 1 29 1 13
OEPA p2 courses 3
Doxorubicin p160mgm
 2
LVPP p4 courses 38 1 6
Chlorambucil p336mgm
 2
Procarbazine p5.6gm
 2
LVPP 6–8 courses 18
Chlorambucil 504–672mgm
 2
Procarbazine 8.4–11.2gm
 2
BEACOPP 5
8 standard courses or
2 dose escalated/6 standard
Cyclophosphamide 5.2–6.4g/m
2
Procarbazine 5.6gm
 2
BEACOPP 1
4 standard courses
Cyclophosphamide 2.6gm
 2
Procarbazine 2.8gm
 2
COPP p2 courses 2
Cyclophosphamide p1gm
 2
Procarbazine p3gm
 2
CHOP/COP p8 courses 58 23 4
Cyclophosphamide p6gm
 2
CHOP/COP 48 courses 81
Maxi-CHOP X6 courses
Cyclophosphamide X6.75gm
 2
MACOP B 6
Doxorubicin 300mgm
 2
Cyclophosphamide 2.1gm
 2
BFM 90/93 3
Cyclophosphamide 3gm
 2
Ifosfamide 12gm
 2
MIME p4 courses 12 0 9
Ifosfamide p20gm
 2
MIME 5–7 courses 2 5 3
Ifosfamide 25–35gm
 2
Chlorambucile p.o. 7 8
1080mg/6 months
HDT/BEAM 13 8
Melphalan 140mgm
 2
Carmustin 300mgm
 2
TBI/cyclophoshamide 18 2
Cyclophosphamide
60mgkg
 1 2
ABVD¼doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP¼cyclophosphamide, doxorubicin, etoposide, procarbazine, prednisone, vincristine, bleomycine;
BEAM¼carmustine, etoposide, cytarabine, melphalan; CHOP¼cyclophosphamide, doxorubicin, vincristine, prednisone; LVPP, chlorambucile, vinblastine, procarbazine,
prednisone; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; MIME, mitoguazone, iphosphamide, methotrexate, etoposide; OEPA,
doxorubicine, vincristine, etoposide, prednisone. Number of patients¼294. BFM 90/93 as described by Seidemann et al, 2001, see reference list.
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three groups: 1: All gonadal hormones within normal range
(Normal), 2: Isolated elevated FSH, with LH, SHBG and
testosterone within normal range (exocrine hypogonadism), 3:
Testosterone below and/or LH above normal range, independent of
FSH (endocrine hypogonadism), admitting that this group
includes some male patients with both endocrine and exocrine
hypogonadism. (Table 2).
Patients with endocrine hypogonadism were further sub-
grouped: A: low testosterone and normal LH/FSH, B: elevated
LH, testosterone normal, C: low testosterone combined with either
elevated LH and/or elevated FSH. (Table 3).
Three patients already on testosterone substitution were
included in subgroup C, assuming they had low testosterone
combined with elevated LH before having started testosterone
substitution.
Table 1C Radiotherapy treatment in the five treatment groups
1. No chemo/low 2. Med-NHL 3. Med-HL 4. High-NHL 5. High-HL
N¼99 N¼73 N¼43 N¼43 N¼36
(%) (%) (%) (%) (%)
Received radiotherapy 89 (90) 43 (59) 37 (86) 36 (84) 26 (72)
Supradiaphragmatic 73 22 24 11 15
Abdominal fields 3 16 3 3 4
InvertedY/Inguinal fields 10 4 9 3 5
TBI 18 2
Other radiation fields 3 1 1 1
Number of patients¼294. HL: Stage I/II: 1980–1982: 2Gy 20, 1982–1998: 1.8Gy 23, 1999 onwards: 1.75Gy 17. Stage III/IV: 1980–1985: 2Gy 20, 1985–1998:
2Gy 20 or 1.8Gy 23, 1999 onwards: 1.75Gy 17. NHL: Low-grade: 2Gy 15 to involved and nearest neighbouring draining lymph node region. High-grade: 2Gy 20 or
1.8Gy 23 if residual masses or initial Bulky disease. TBI (total body irradiation): 1.3Gy 10.
Table 2 Patients characteristics
All Normal gonadal hormones Exocrine hypogonadism Endocrine hypogonadism
N¼294 N¼144 N¼60 N¼90
(49%) (20%) (31%)
Median (range) age at diagnosis
a 33 (6–49) 31 (6–49) 33 (11–48) 35 (14–49)
Median (range) age at survey
b 49 (21–73) 47 (21–68) 47 (25–67) 54 (28–73)
Median (range) observation time
c (years) 15 (4–28) 14 (4–26) 16 (4–28) 17 (4–26)
No. of patients
(% in this group)
No. of patients
(% in this group)
No. of patients
(% in this group)
No. of patients
(% in this group)
HL 165 (56) 79 (55) 27 (45) 59 (66)
Stage I/II
d 105 62 12 31
Stage III/IV
d 60 17 15 28
First relapse 27 5 8 14
X2nd relapse 5 5
NHL 129 (44) 65 (45) 33 (55) 31 (34)
Stage I/II
d 67 45 7 15
Stage III/IV
d 62 20 26 16
First relapse 35 8 17 10
X2nd relapse 12 2 8 2
HL/NHL 7 3 1 3
Treatment group
No. of patients
(% in this group) No. of patients No. of patients No. of patients
1. No chemo/Low 99 (34) 78 3 18
2. Med-NHL 73 (25) 45 13 15
3. Med-HL 43 (15) 11 11 21
4. High-NHL 43 (15) 7 20 16
HDT/BEAM 13 1 8 4
TBI/cyclophoshamide 18 1 7 10
5. High-HL 36 (12) 3 13 20
HDT/BEAM 8 4 4
TBI/cyclophoshamide 2 2
Exocrine hypogonadism: FSH412.0Ul
 1; testosterone, SHBG, LH within normal ranges. Endocrine hypogonadism: Either testosterone o9.0nmoll
 1 and/or elevated LH.
Treatment groups: 1: No/Low gonadotoxic chemotherapy±radiotherapy. 2: Medium gonadotoxic chemotherapy±radiotherapy NHL. 3: Medium gonadotoxic
chemotherapy±radiotherapy HL. 4: High gonadotoxic chemotherapy±radiotherapy NHL. 5: High gonadotoxic chemotherapy±radiotherapy HL.
aAge at diagnosis:
P¼0.017, Kruskal–Wallis (among groups of gonadal hormones).
bAge at survey: P¼0.001, Kruskal–Wallis (among groups of gonadal hormones).
cObservation time: time from
diagnosis to 1 January 2007 (in years).
dStage at initial diagnosis. HDT¼high dose chemotherapy with autologous stem cell support. HL/NHL¼patients registered with both
diagnosis in the lymphoma database.
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sEthical considerations
Informed written consent was obtained from all responders. The
Regional Committee for Medical Research Ethics, Health Region
South, Norway and the Institutional Review Board and the Chief
Privacy Officer at the NRH approved the study.
Statistical analyses
Data were described with medians and ranges. Continuous
variables were compared using Mann–Whitney Wilcoxon and
Kruskal–Wallis tests. Crude associations between categorical
variables were computed with w
2 tests.
Age at diagnosis was categorised into four groups: 1: 6–25 years,
2: 26–34 years, 3: 35–41 years, 4: 42–50 years. Age at survey
(January 2007) was categorised as follows: 1: 21–39 years, 2: 40–49
years, 3: 50–56 years, 4: 57–75 years. Observation time was
calculated from date of first diagnosis to 1 January 2007, and was
further categorised in three groups: 1: 4–10 years, 2: 11–20 years,
3: 21–28 years.
Multinomial regression analyses were performed, the dependent
variable being gonadal hormones divided into three
categories: (1¼normal (reference), 2¼exocrine hypogonadism,
3¼endocrine hypogonadism). The model was adjusted for the five
treatment groups, age groups and observation time. As initial
analyses revealed that observation time was not significant, this
variable was excluded from the final model. Finally, two multi-
variable models were fitted; one including treatment groups and
age at survey as independent variables, the other included
treatment groups and age at diagnosis. The odds ratios for both
exocrine and endocrine hypogonadism were similar in both
models, possibly due to a strong correlation between age at
diagnosis and age at survey. Only results from the model fitted
with treatment and age at survey are presented.
Po0.05 were considered statistically significant (all tests were
two-sided). All analyses were performed using SPSS 13 for
Windows.
RESULTS
Patients’ characteristics
In all 653 patients met the inclusion criteria and were invited to
participate by mail (360 HL, 293 NHL). A total of 294 (45%) had
their gonadal hormones assessed and were included in this study
(compliers).
The compliers and non-compliers (survivors without blood
samples) were similar as to lymphoma diagnosis and treatment
groups. However, the compliers were older than the non-compliers
both at diagnosis (median 33 vs 31 years (P¼0.006)) and at survey
(median 49 vs 45 years (Po0.001)), and had significantly longer
observation time (median 15 vs 13 years (P¼0.028)).
Of the 294 compliers, 165 (56%) had been treated for HL and 129
(44%) for NHL. Sixty-four percent (n¼187) had received
chemotherapy and radiotherapy, 63 (21%) had had chemotherapy
only and 44 patients (15%) had undergone radiotherapy only.
Median age at diagnosis was 33 years (range, 6–49), median age at
survey was 49 years (range, 21–73), and median observation time
was 15 years (range, 4–28) (Table 2).
As expected, age at survey and age at diagnosis were higher in
NHLSs compared with HLSs, without difference in observation
time between these groups.
Single values of FSH, LH, Testosterone and SHBG
The median FSH value for all patients was 8.5Ul
 1 (range,
0.4–67.0Ul
 1). Forty-one percent had FSH values 4 12.0Ul
 1,
and in 26% the FSH value were 4 20.0Ul
 1. The median LH value
was 6.0Ul
 1 (range, 1.2–45.8Ul
 1), and 16% of the patients had
elevated LH (410.0Ul
 1) (Table 4).
The median testosterone value was 12.9nmoll
 1 (range,
1.7–33.9nmoll
 1), with 20% of the patients having testosterone
value o9.0nmoll
 1. The median value of the testosterone/
SHBG-ratio was 0.37. Of all patients, 14% had a testosterone/
SHBG ratio o0.25.
Table 3 Characteristics of the patients with endocrine hypogonadism, and subgroups
A. B. C.
Endocrine Low testosterone Elevated LH Low testosterone
hypogonadism LH/FSH normal Testosterone normal Elevated LH or FSH or both
a
N¼90 N¼27 N¼30 N¼33
Median (range) age at diagnosis 35 (14–49) 33 (18–46) 40 (18–49) 33 (14–49)
Median (range) age at survey 54 (28–73) 48 (28–59) 54 (29–68) 57 (33–73)
Median (range) observation time 17 (4–26) 14 (4–25) 16 (4–26) 20 (4–26)
Median (range) Testosterone/SHBG ratio 0.27 (0.05–0.85) 0.33 (0.13–0.49) 0.34 (0.17–0.72) 0.23 (0.05–0.85)
Diagnosis % within this group
HL 59 (66) 22 15 22
NHL 31 (34) 5 15 11
Treatment group
1. No chemo/Low 18 15 2 1
2. Med-NHL 15 4 5 6
3. Med-HL 21 3 6 12
4. High-NHL 16 1 10 5
HDT/BEAM 4 4
TBI/cyclophosphamide 10 1 4 5
5. High-HL 20 4 7 9
HDT/BEAM 4 1 3
TBI/cyclophosphamide 2 1 1
Treatment groups: 1: No/Low gonadotoxic chemotherapy±radiotherapy. 2: Medium gonadotoxic chemotherapy±radiotherapy NHL. 3: Medium gonadotoxic
chemotherapy±radiotherapy HL. 4: High gonadotoxic chemotherapy±radiotherapy NHL. 5: High gonadotoxic chemotherapy±radiotherapy HL.
aElevated FSH and low
testosterone: n¼17, elevated both LH and FSH and low tesosterone n¼16.
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the individual levels of FSH, LH and SHBG (Po0.001). For
testosterone, no such association with age at survey was observed.
However, the testosterone/SHBG-ratio decreased significantly with
increasing age (Po0.001).
There was also a significant association between the individual
levels of both FSH, LH (Po0.001) and SHBG (P¼0.042) and
treatment groups. The median level of FSH and LH increased
significantly in all other treatment groups compared with patients
with no/low gonadotoxic chemotherapy (Po0.001–Po0.02). For
testosterone and testosterone/SHBG-ratio no association with
treatment groups was found.
Groups of gonadal dysfunction
Forty-nine percent (n¼144) had all gonadal hormones within
normal ranges, 60 (20%) displayed exocrine hypogonadism
(isolated elevated FSH, with LH, SHBG and testosterone within
normal range) and in almost one-third (n¼90, 30%) the hormone
levels were compatible with endocrine hypogonadism (testoster-
one below and/or LH above normal range, independent of FSH).
There was a statistically significant association between treatment
group and groups of gonadal dysfunction (Po0.001). After
treatment with no/low gonadotoxic chemotherapy 79% had
normal gonadal hormones, whereas the comparable figures were
62% after med-NHL, 26% after med-HL, 16% after high-NHL and
8% after high-HL (Figure 1; (Table 2).
Of the 41 patients treated with high dose chemotherapy and
autologous stem cell support (HDT), 19 men had exocrine and 20
endocrine hypogonadism. Only two patients had normal gonadal
hormones.
Stage at diagnosis was significantly associated with the group of
hormonal dysfunction (Po0.001). In patients with stage I/II at
diagnosis 62% had normal gonadal hormones, 11% displayed
exocrine hypogonadism and endocrine hypogonadism was de-
monstrated in 27%. The comparable numbers in patients with
stage III/IV were: normal gonadal hormones in 30%, exocrine
hypogonadism in 34% and endocrine hypogonadism in 36%.
The patients with endocrine hypogonadism were older both at
diagnosis (P¼0.004) and at survey (Po0.001) and they had a
longer median observation time (P¼0.047) than those with
normal gonadal hormones. There was no difference in age at
diagnosis or survey and in observation times between patients with
exocrine hypogonadism and patients with normal gonadal
hormones.
Multinomial regression analyses
Compared to those treated with no/low gonadotoxic chemotherapy
patients from all other treatment groups had significantly elevated
odds ratios (OR) for exocrine hypogonadism (Table 5). Patients in
the med-NHL group were 6.3 (95% CI: 1.7–23.8) times more likely
to suffer from exocrine hypogonadism compared to those treated
with no/low gonadotoxic chemotherapy. The comparable ORs for
the other groups were 25.7 (95% CI: 6.2–107.0) after med-HL, 73.3
(95% CI: 17.2–312.2) after high-NHL and 112.0 (95% CI: 20.1–
625.2) after high-HL. Age at survey was not significantly associated
with exocrine hypogonadism.
In addition, compared to the group treated with no/low
gonadotoxic chemotherapy, patients from the other treatment
groups, except those in the med-NHL group, had significantly
elevated risk also for endocrine hypogonadism. Patients in the
med-HL were 8.0 (95% CI: 3.2–20.4) times more likely to have
endocrine hypogonadism compared to those treated with no/low
gonadotoxic chemotherapy, whereas the comparable ORs for high-
NHL were 10.5 (95% CI: 3.6–30.6) and 37.2 (95% CI: 9.4–147.7)
for high-HL.
Table 4 Serum levels of LH, FSH, testosterone, SHBG and testosterone/SHBG ratio related to age at survey and treatment groups
Age at survey groups Treatment groups
1234 1234 5
All 21–39yrs 40–49yrs 50–56yrs 57–75yrs No/low med-NHL med-HL high-NHL high-HL
N¼294 N¼66 N¼86 N¼75 N¼67 N¼99 N¼73 N¼43 N¼43 n¼36
FSH
Median 8.5 5.9 6.4 8.5 17.7 4.7 7.2 19.8 19.2 20.5
Range (Ul
 1) 0.4–67.0 1.0–32.0 1.4–67.0 2.3–56.4 0.4–63.3 1.0–40.4 1.4–41 2.2–56.4 2.3–67.0 0.4–53.2
FSH 412 Ul
 1 41% 31% 32% 43% 59% 5% 33% 70% 81% 81%
LH
Median 6.0 5.7 5.5 5.7 7.7 4.4 5.4 7.9 8.2 8.2
Range Ul
 1 1.2–45.8 1.8–14.5 1.7–20.1 1.8–26.3 1.2–45.8 1.7–16.7 1.2–43.6 1.9–19.6 2.3–45.8 4.5–20.1
LH 410Ul
 1 16% 10% 7% 23% 25% 3% 12% 30% 29% 32%
Testosterone
Median 12.9 13.6 13.7 12.8 11.1 12.6 14.3 10.2 14.2 11.3
Range (nmoll
 1) 1.7–33.9 4.4–28.1 4.7–33.9 4.3–26.6 1.7–23.0 5.2–27.1 1.7–30.4 5.4–33.9 4.3–22.4 4.4–29.6
Testosterone o9nmoll
 1 20% 12% 16% 24% 28% 17% 14% 33% 15% 33%
SHBG
Median 34 26 32 41 42 33 40 31 32 29
Range (nmoll
 1) 10–132 10–84 11–71 17–84 14–132 10–84 13–132 16–70 14–66 14–76
Testosterone/SHBG ratio
Median 0.37 0.49 0.42 0.32 0.28 0.42 0.35 0.31 0.36 0.39
Range 0.05–1.02 0.18–1.02 0.13–0.85 0.14–0.65 0.05–0.56 0.13–0.78 0.05–0.84 0.14–1.02 0.1–0.71 0.1–0.85
Testosterone/SHBG ratio o0.25 14% 3% 9% 15% 30% 13% 10% 24% 15% 14%
Age at survey categorised in four groups: 1: 21–39 years, 2: 40–49 years, 3: 50–56 years, 4: 57–75 years. Treatment groups: 1: No/Low gonadotoxic
chemotherapy±radiotherapy. 2: Medium gonadotoxic chemotherapy±radiotherapy NHL. 3: Medium gonadotoxic chemotherapy±radiotherapy HL. 4: High gonadotoxic
chemotherapy±radiotherapy NHL. 5: High gonadotoxic chemotherapy±radiotherapy HL.
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sMen aged above 50 years at survey were about five times more
likely to have endocrine hypogonadism compared with those less
than 40 years at survey.
The ORs for both isolated elevated FSH and endocrine
hypogonadism increased more in HL survivors compared with
NHL survivors in comparable treatment groups.
Overall, treatment with medium and highly gonadotoxic
chemotherapy for both HL and NHL had a stronger effect on
exocrine than on endocrine hypogonadism.
Patients with endocrine hypogonadism (n¼90)
Patients with low testosterone combined with elevated LH and/or
FSH displayed significantly longer observation times than the
other two subgroups (P¼0.001). This group had also significantly
lower testosterone/SHBG ratios than the other subgroups
(P¼0.003/P¼0.001). (Table 3).
DISCUSSION
In this cross-sectional observational study gonadal hormones were
assessed in 294 male survivors after treatment for both HL and
NHL. About half had all gonadal hormones within normal range,
20% had isolated elevated FSH, and almost one-third had gonadal
hormones compatible with our definition of endocrine hypo-
gonadism. Compared to those treated with no/low gonadotoxic
chemotherapy, patients from all other treatment groups had
significantly elevated risk for exocrine hypogonadism. In addition,
patients from the other treatment groups, except those in the med-
NHL group, had a significantly elevated risk also for endocrine
hypogonadism compared to the group treated with no/low
gonadotoxic chemotherapy.
We confirm the results from our previous study in HLSs, where
we observed exocrine gonadal damage related to the type,
cumulative dose and intensity of chemotherapy, assessed by
post-treatment paternity (Kiserud et al, 2007). This study shows
for the first time that the same categorization of chemotherapy in
low, medium and highly gonadotoxic treatment can be useful also
when exploring endocrine hypogonadism.
Forty-one percent of our lymphoma survivors had elevated FSH.
Although this figure seems comparable to 35%, reported by van
der Kaaij et al (2007), important differences should not be
Table 5 Odds for exocrine and endocrine hypogonadism
OR 95% CI P-value
Exocrine hypogonadism
Treatment
1.No/low Reference
2.Med-NHL 6.3 1.7–23.8 0.007
3.Med-HL 25.7 6.2–107.0 o0.001
4.High-NHL 73.3 17.2–312.2 o0.001
5.High-HL 112.0 20.1–625.2 o0.001
Age at survey
1: 21–39 years Reference
2: 40–49 years 1.0 0.4–2.7 0.96
3: 50–56 years 1.0 0.3–3.0 0.99
4: 57–75 years 2.0 0.7–5.8 0.19
Endocrine hypogonadism
Treatment
1.No/low Reference
2.Med-NHL 1.1 0.5–2.5 0.86
3.Med-HL 8.0 3.2–20.4 o0.001
4.High-NHL 10.5 3.6–30.6 o0.001
5.High-HL 37.2 9.4–147.7 o0.001
Age at survey
1: 21–39 years Reference
2: 40–49 years 1.5 0.5–3.9 0.46
3: 50–56 years 5.0 1.9–13.2 0.001
4: 57–75 years 4.9 1.8–13.7 0.002
Multinomial regression analysis. Treatment groups: 1: No/Low gonadotoxic
chemotherapy±radiotherapy. 2: Medium gonadotoxic chemotherapy±radiotherapy
NHL. 3: Medium gonadotoxic chemotherapy±radiotherapy HL. 4: High gonadotoxic
chemotherapy±radiotherapy NHL. 5: High gonadotoxic chemotherapy±radio-
therapy HL.
0
10
20
30
40
50
60
70
80
No chemo /
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Normal gonadal
hormones
Exocrine
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Figure 1 Proportions of male lymphoma survivors with normal gonadal hormones, exocrine and endocrine hypogonadism. Normal gonadal hormones:
testosterone, SHBG, LH and FSH within normal ranges. Exocrine hypogonadism: isolated elevated FSH. Testosterone, SHBG, LH, within normal ranges.
Endocrine hyogonadism: elevated LH and/or low testosterone. Treatment groups: No chemo/low: radiotherapy only/low gonadotoxic chemotherapy, Med-
NHL: medium gonadotoxic chemotherapy for non-Hodgkin’s lymphoma (NHL), Med-HL: medium gonadotoxic chemotherapy for Hodgkin’s lymphoma
(HL), High-NHL: highly gonadotoxic chemotherapy for NHL, High-HL: highly gonadotoxic chemotherapy for HL.
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soverseen. Our series included men with initially advanced disease
and men treated for relapse. Many of our patients thus have had
more intensive chemotherapy than usually given to patients with
stage I/II. In addition, we examined both HLSs and NHLSs, which
make the two series less comparable. Finally, our median
observation time was 15 years, compared with the median 32
months follow-up period reported by van der Kaaij et al (2007).
We thus consider our proportion of FSH elevation as definite,
whereas one still can expect some recovery of spermatogenesis
with longer follow up in early stage lymphoma patients with
limited treatment.
This study confirms the low risk of elevated FSH in HLSs after
treatment with ABVD-like regimens or radiotherapy only com-
pared with other combinations incorporating alkylating agents
(Whitehead et al, 1982; Viviani et al, 1985, 1991; van der Kaaij
et al, 2007). In addition, we observed that the probability of
exocrine hypogonadism increased with treatment intensity also in
NHLSs, whereas age at survey was of no significance.
Compared to the no/low gonadotoxic chemotherapy group
the risk of endocrine hypogonadism increased for all treatment
groups except for NHLSs treated mainly with CHOP-based
chemotherapy (med-NHL). Intensification of chemotherapy
increased the risk of endocrine gonadal failure more in HLSs
than in NHLSs. This probably reflects that chemotherapy regimens
used for HL generally are more gonadotoxic than those used
for NHL. This difference may also be due to differences in the
pre-treatment gonadal function between HLSs and NHLSs,
pointed out by Botchan et al (1997). Increasing risk
of endocrine hypogonadism along with chemotherapy intensifica-
tion has also been documented for testicular cancer survivors
(Nord et al, 2003).
In this paper, we followed the categorisation for endocrine
hypogonadism based on elevated LH and normal testosterone
(compensated hypogonadism) or low testosterone with or without
elevated LH proposed by Howell et al (1999). Our data indicated that
the duration of the observation time might be associated with the
development of an uncompensated hypogonadism, as this period
was longer in subgroup 3C than in subgroup 3A and 3B. However,
our patient sample also shows a more diverse picture, with 27 of 57
patients with low testosterone having normal LH (subgroup 3A).
Similarly, Greenfield et al (2007) reported low testosterone values
(o10nmoll
 1) in 24 (13.6%) of 176 patients, but only eight of these
men had increased LH. This may reflect that causes of endocrine
hypogonadism in cancer survivors may be more complex than
previously described. Chemotherapy and/or radiation-induced
damage may develop either in the gonads, the hypothalamus–
pituitary axis or as a combination of these two. To verify the
influence of secondary hypogonadism, the pituitary function has to
be tested by a gonadotropin-releasing hormone test, which was not
performed in our patients. Further, except for the pathway through
the hypothalamus–pituitary axis and the release of GnRH, the
mechanisms related to Leydig cell dysfunction after cancer treatment
is not well characterised. The possible negative influence of
germinative dysfunction on Leydig cells suggested by Howell et al
(1999) is thus interesting, but requires further examination.
The blood samples were generally taken during the morning. We
were aware of the risk of falsely low testosterone in case of afternoon
blood sampling and tried to avoid this possibility as much as possible.
However, we completely cannot exclude such sampling as explanation
in some patients in subgroup 3A. For most of these patients, the
results have been confirmed in a subsequent morning sample taken at
the hospital’s outpatient clinic, as patients with gonadal hormones
indicating hypogonadism were invited to clinical examination and a
control morning blood sample. Finally, a low testosterone value with
normal LH and FSH may also be due to a random low testosterone
value caused by, for instance patients’ stress.
Testosterone deficiency in adult males has been associated with
declining bone mass, muscle strength, reduced energy levels and
altered sexual function (Araujo et al, 2007). In male cancer
survivors, Howell et al (2000) reported reduced bone mineral
density in patients with mild Leydig cell impairment, and
testosterone levels has been reported to be negatively correlated
to insulin, total body fat mass/total trunk fat mass and BMI
(Huddart and Norman, 2003; Greenfield et al, 2007). With this
background, it is of clinical importance to identify male cancer
survivors with endocrine hypogonadism. In this context, it is
surprising that only three of the included patients reported
testosterone substitution therapy at the time of the survey, whereas
endocrine hypogonadism was found in one-third of our patients.
Testosterone replacement therapy is a challenging issue in both
male cancer survivors and in the general male population. Age has
a significant influence on physiological testosterone levels. To
evaluate endocrine hypogonadism at least two morning blood
samples are needed and clinical symptoms, age and possible
contraindications for testosterone substitution have to be con-
sidered. Owing to these caveats our study patients’ with endocrine
hypogonadism identified in this study were offered repeated
hormone analyses and clinical examination at the outpatient clinic
before any testosterone substitution was initiated.
There are some limitations to be discussed:
The compliers were older at survey than the non-compliers. This
may have caused a biased patient sample with a slightly higher
proportion of hypogonadism in our patient sample than in the
total population of male lymphoma survivors.
Our patients’ age ranged from 21 to 73 years at survey and we
found a fivefold increase in the risk of endocrine hypogonadism in
men aged above 50 years at survey compared to those less than 40
years at survey. Similarly, Howell et al (1999) reported increasing
risk of chemotherapy-induced Leydig cell damage with increasing
age, and an age-dependent decline in testosterone levels was
reported by Greenfield et al (2007). Studies from the general
population have shown age-related decrease in testosterone values
(Svartberg et al, 2003; Mohr et al, 2005). As our normal range for
testosterone was not age adjusted, this may have lead to a
comparatively broad allocation of older men to the group of
endocrine hypogonadism. As a further limitation we could not
consider chronic co-morbidity or any long-lasting medication in
our patients, which might also have influenced our findings.
Seven patients registered in the database with both HL and NHL
had their gonadal hormones assessed, and were grouped according
to their first diagnosis. This may have biased the results because
their treatment consisted of combinations of different types of
chemotherapy.
The strength of this cross-sectional study is that it consists of a
large series of male survivors after both HL and NHL with known
treatment details and gonadal hormones assessed by a single
laboratory. We achieved a compliance of 45%, which we consider
satisfactory taken into account that this long-term follow-up
survey implied blood sampling at a GP’s office.
The results of this study implicate that gonadal hormones
should be assessed regularly in male lymphoma survivors,
especially after treatment with high-dose alkylating agents and
HDT and in male patients 50 years and older. If gonadal hormones
indicate hypogonadism, further analyses and clinical evaluation
should evaluate the need of testosterone substitution to avoid the
development of serious health problems.
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